Mechanism of Cardiac Pathogenesis and Cardiotoxicity of Anti- COVID-19 Drugs

Author(s): Ashif Iqubal, Farazul Hoda, Abul Kalam Najmi, Syed Ehtaishamul Haque*

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Volume 2 , Issue 9 , 2021

Article ID: e030821189346
Become EABM
Become Reviewer
Call for Editor


Novel coronavirus (nCoV-19) infection has been declared a pandemic by WHO. More than 223 countries are under the attack of this emergency situation. Primarily, pneumocytes encountered by the nCoV-19 via ACE-2 receptor cause pulmonary edema, damage to alveolar cells, production of inflammatory cells, and hypoxia. It has been found that patients with co-existing cardiovascular diseases are more prone to the infection, and severe cardiovascular dysfunction was further observed when infected with nCoV-19. There is no substantial mechanism available for the pathogenesis of this cardiovascular dysfunction; therefore, we herein present a possible mechanistic approach of cardio-toxicity by nCov-19 infection. The hypothesis of this study is based on immunopathology of nCoV-19 in pneumocytes, presence of ACE-2 on cardiomyocytes membrane, cytokine storm, genomic analysis of virus in cardiac tissue, and several reports published on the cardiovascular complications in nCoV-19 across the globe. We have also analyzed the cardiotoxic profile of recently used repurposed and investigational drugs and highlighted their possible cardiotoxic consequences and drug interactions with cardiovascular medicines, such as statins and anti-coagulants.

Keywords: COVID-19, cardiac complications, cytokine storm, pneumocytes, immunopathology, inflammation, cardiac troponin T, ACE-2 receptor.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 21 December, 2020
Article ID: e030821189346
Pages: 6
DOI: 10.2174/2666796701999201222113227

Article Metrics

PDF: 11